Natalia Bustos Sierra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Natalia Bustos Sierra has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Toon Braeye
Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium
2 shared publications Ahmed Farah
Public Health Agency of Sweden, Stockholm, Sweden
1 shared publicationAlain Levêque
Centre de Recherche Epidémiologie, Biostatistiques, Recherche Clinique, School of Public Health, Université Libre de Bruxelles (U.L.B.), Route de Lennik 808, CP 596, 1070 Brussels, Belgium
1 shared publication- Alena Chalupka
Austrian Agency for Health and Food Safety, Vienna, Austria
1 shared publication - Alfred Bernard
Louvain Centre for Toxicology and Applied Pharmacology, Institute of Experimental and Clinical Research (IREC), Catholic University of Louvain, Brussels, Belgium
1 shared publication Alina Weigel
Hessisches Landesamt für Gesundheit und Pflege, Dillenburg, Germany
1 shared publication
Latest Publications
- Open Access
Mortality Baselines and Excess Mortality Events in Belgian and Greek Cities Using Singular Spectrum Analysis
Background: Excess mortality estimates depend on an expected baseline, an unobservable quantity typically derived from models with prescribed functional forms and short reference periods that exclude exceptional events. Singular Spectrum Analysis (SSA) offers a nonparametric alternative but requires subjective component selection and is sensitive to outliers. We combined SSA with automated component selection and outlier interpolation to estimate long-term baselines and compile a catalog of excess mortality events (EMEs). Methods: We analyzed weekly all-cause mortality (2015–2024) for six metropolitan areas with contrasting climatic, demographic, and epidemiological contexts: Brussels, Antwerp, and Liège (Belgium), and Athens, Thessaloniki, and Larisa (Greece). SSA was applied to standardized log-mortality rates; components were selected using Monte Carlo SSA, and COVID-19 periods were interpolated iteratively. EMEs were defined as weeks exceeding a quasi-Poisson two-z-score threshold, then screened for coincidence with heat waves, cold waves, COVID-19 periods, and influenza epidemics. Results: Baselines were consistent within countries: annual cycles in Belgium, with an additional significant semiannual cycle in Greece reflecting summer mortality. We cataloged 170 EMEs spanning 456 weeks and 14,210 excess deaths. Pandemic weeks accounted for 77% of excess mortality, and 96 weeks coincided with temperature extremes; 56 EMEs, representing 3.7% of excess mortality, remained unmatched. Conclusions: SSA yields reproducible, low-assumption baselines that capture country-specific seasonality. Because flexible baselines can absorb recurrent seasonal mortality, component selection is a substantive choice that should be reported explicitly, together with its sensitivity.
Open AccessMortality Baselines and Excess Mortality Events in Belgian and Greek Cities Using Singular Spectrum Analysis
Background: Excess mortality estimates depend on an expected baseline, an unobservable quantity typically derived from models with prescribed functional forms and short reference periods that exclude exceptional events. Singular Spectrum Analysis (SSA) offers a nonparametric alternative but requires subjective component selection and is sensitive to outliers. We combined SSA with automated component selection and outlier interpolation to estimate long-term baselines and compile a catalog of excess mortality events (EMEs). Methods: We analyzed weekly all-cause mortality (2015–2024) for six metropolitan areas with contrasting climatic, demographic, and epidemiological contexts: Brussels, Antwerp, and Liège (Belgium), and Athens, Thessaloniki, and Larisa (Greece). SSA was applied to standardized log-mortality rates; components were selected using Monte Carlo SSA, and COVID-19 periods were interpolated iteratively. EMEs were defined as weeks exceeding a quasi-Poisson two-z-score threshold, then screened for coincidence with heat waves, cold waves, COVID-19 periods, and influenza epidemics. Results: Baselines were consistent within countries: annual cycles in Belgium, with an additional significant semiannual cycle in Greece reflecting summer mortality. We cataloged 170 EMEs spanning 456 weeks and 14,210 excess deaths. Pandemic weeks accounted for 77% of excess mortality, and 96 weeks coincided with temperature extremes; 56 EMEs, representing 3.7% of excess mortality, remained unmatched. Conclusions: SSA yields reproducible, low-assumption baselines that capture country-specific seasonality. Because flexible baselines can absorb recurrent seasonal mortality, component selection is a substantive choice that should be reported explicitly, together with its sensitivity.
- Open Access
- 11 April 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (15) , 2400178
Excess mortality in Europe coincides with peaks of COVID-19, influenza and respiratory syncytial virus (RSV), November 2023 to February 2024
Since the end of November 2023, the European Mortality Monitoring Network (EuroMOMO) has observed excess mortality in Europe. During weeks 48 2023–6 2024, preliminary results show a substantially increased rate of 95.3 (95% CI: 91.7–98.9) excess all-cause deaths per 100,000 person-years for all ages. This excess mortality is seen in adults aged 45 years and older, and coincides with widespread presence of COVID-19, influenza and respiratory syncytial virus (RSV) observed in many European countries during the 2023/24 winter season.
- 11 April 2024
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 29 (15) , 2400178
Open AccessExcess mortality in Europe coincides with peaks of COVID-19, influenza and respiratory syncytial virus (RSV), November 2023 to February 2024
Since the end of November 2023, the European Mortality Monitoring Network (EuroMOMO) has observed excess mortality in Europe. During weeks 48 2023–6 2024, preliminary results show a substantially increased rate of 95.3 (95% CI: 91.7–98.9) excess all-cause deaths per 100,000 person-years for all ages. This excess mortality is seen in adults aged 45 years and older, and coincides with widespread presence of COVID-19, influenza and respiratory syncytial virus (RSV) observed in many European countries during the 2023/24 winter season.
- Open Access
- 26 June 2023
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 78 (8) , 2061-2065
Persistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in Belgium
In August 2018, a public health alert was issued in Belgium regarding clusters of impetigo cases caused by the epidemic European fusidic acid-resistant impetigo clone (EEFIC) of Staphylococcus aureus. As a result, the Belgian national reference centre (NRC) was commissioned to update the epidemiology of S. aureus causing community-onset skin and soft tissues infection (CO-SSTI) to assess the proportion of EEFIC among them. For 1 year, Belgian clinical laboratories were asked to send their first three S. aureus isolated from CO-SSTI each month. Isolates were tested for antimicrobial susceptibility to oxacillin, mupirocin and fusidic acid. Resistant isolates were also spa typed and tested for the presence of the genes encoding the Panton–Valentine leucocidin, the toxic shock syndrome toxin and the exfoliatins A and B. MLST clonal complexes were deduced from the spa types. Among the 518 S. aureus strains analysed, 487 (94.0%) were susceptible to oxacillin. Of these, 79 (16.2%) were resistant to fusidic acid, of which 38 (48.1%) belonged to the EEFIC. EEFIC isolates were mostly isolated from young patients with impetigo and showed a seasonal late summer peak. These results suggest the persistence of EEFIC in Belgium. Furthermore, its prevalence may lead to reconsideration of the treatment guidelines for impetigo.
- 26 June 2023
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 78 (8) , 2061-2065
Open AccessPersistence of the Staphylococcus aureus epidemic European fusidic acid-resistant impetigo clone (EEFIC) in Belgium
In August 2018, a public health alert was issued in Belgium regarding clusters of impetigo cases caused by the epidemic European fusidic acid-resistant impetigo clone (EEFIC) of Staphylococcus aureus. As a result, the Belgian national reference centre (NRC) was commissioned to update the epidemiology of S. aureus causing community-onset skin and soft tissues infection (CO-SSTI) to assess the proportion of EEFIC among them. For 1 year, Belgian clinical laboratories were asked to send their first three S. aureus isolated from CO-SSTI each month. Isolates were tested for antimicrobial susceptibility to oxacillin, mupirocin and fusidic acid. Resistant isolates were also spa typed and tested for the presence of the genes encoding the Panton–Valentine leucocidin, the toxic shock syndrome toxin and the exfoliatins A and B. MLST clonal complexes were deduced from the spa types. Among the 518 S. aureus strains analysed, 487 (94.0%) were susceptible to oxacillin. Of these, 79 (16.2%) were resistant to fusidic acid, of which 38 (48.1%) belonged to the EEFIC. EEFIC isolates were mostly isolated from young patients with impetigo and showed a seasonal late summer peak. These results suggest the persistence of EEFIC in Belgium. Furthermore, its prevalence may lead to reconsideration of the treatment guidelines for impetigo.
- Open Access
- 12 July 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (14) , 8531
Assessment of the Feasibility of a Future Integrated Larger-Scale Epidemiological Study to Evaluate Health Risks of Air Pollution Episodes in Children
Air pollution exposure can lead to exacerbation of respiratory disorders in children. Using sensitive biomarkers helps to assess the impact of air pollution on children’s respiratory health and combining protein, genetic and epigenetic biomarkers gives insights on their interrelatedness. Most studies do not contain such an integrated approach and investigate these biomarkers individually in blood, although its collection in children is challenging. Our study aimed at assessing the feasibility of conducting future integrated larger-scale studies evaluating respiratory health risks of air pollution episodes in children, based on a qualitative analysis of the technical and logistic aspects of a small-scale field study involving 42 children. This included the preparation, collection and storage of non-invasive samples (urine, saliva), the measurement of general and respiratory health parameters and the measurement of specific biomarkers (genetic, protein, epigenetic) of respiratory health and air pollution exposure. Bottlenecks were identified and modifications were proposed to expand this integrated study to a higher number of children, time points and locations. This would allow for non-invasive assessment of the impact of air pollution exposure on the respiratory health of children in future larger-scale studies, which is critical for the development of policies or measures at the population level.
- 12 July 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (14) , 8531
Open AccessAssessment of the Feasibility of a Future Integrated Larger-Scale Epidemiological Study to Evaluate Health Risks of Air Pollution Episodes in Children
Air pollution exposure can lead to exacerbation of respiratory disorders in children. Using sensitive biomarkers helps to assess the impact of air pollution on children’s respiratory health and combining protein, genetic and epigenetic biomarkers gives insights on their interrelatedness. Most studies do not contain such an integrated approach and investigate these biomarkers individually in blood, although its collection in children is challenging. Our study aimed at assessing the feasibility of conducting future integrated larger-scale studies evaluating respiratory health risks of air pollution episodes in children, based on a qualitative analysis of the technical and logistic aspects of a small-scale field study involving 42 children. This included the preparation, collection and storage of non-invasive samples (urine, saliva), the measurement of general and respiratory health parameters and the measurement of specific biomarkers (genetic, protein, epigenetic) of respiratory health and air pollution exposure. Bottlenecks were identified and modifications were proposed to expand this integrated study to a higher number of children, time points and locations. This would allow for non-invasive assessment of the impact of air pollution exposure on the respiratory health of children in future larger-scale studies, which is critical for the development of policies or measures at the population level.
- Open Access
- 13 November 2020
- Published by Springer Nature in Archives of Public Health
- Vol. 78 (1) , 1-8
All-cause mortality supports the COVID-19 mortality in Belgium and comparison with major fatal events of the last century
Background: The COVID-19 mortality rate in Belgium has been ranked among the highest in the world. To assess the appropriateness of the country’s COVID-19 mortality surveillance, that includes long-term care facilities deaths and deaths in possible cases, the number of COVID-19 deaths was compared with the number of deaths from all-cause mortality. Mortality during the COVID-19 pandemic was also compared with historical mortality rates from the last century including those of the Spanish influenza pandemic. Methods: Excess mortality predictions and COVID-19 mortality data were analysed for the period March 10th to June 21st 2020. The number of COVID-19 deaths and the COVID-19 mortality rate per million were calculated for hospitals, nursing homes and other places of death, according to diagnostic status (confirmed/possible infection). To evaluate historical mortality, monthly mortality rates were calculated from January 1900 to June 2020. Results: Nine thousand five hundred ninety-one COVID-19 deaths and 39,076 deaths from all-causes were recorded, with a correlation of 94% (Spearman’s rho, p < 0,01). During the period with statistically significant excess mortality (March 20th to April 28th; total excess mortality 64.7%), 7917 excess deaths were observed among the 20,159 deaths from all-causes. In the same period, 7576 COVID-19 deaths were notified, indicating that 96% of the excess mortality were likely attributable to COVID-19. The inclusion of deaths in nursing homes doubled the COVID-19 mortality rate, while adding deaths in possible cases increased it by 27%. Deaths in laboratory-confirmed cases accounted for 69% of total COVID-19-related deaths and 43% of in-hospital deaths. Although the number of deaths was historically high, the monthly mortality rate was lower in April 2020 compared to the major fatal events of the last century. Conclusions: Trends in all-cause mortality during the first wave of the epidemic was a key indicator to validate the Belgium’s high COVID-19 mortality figures. A COVID-19 mortality surveillance limited to deaths from hospitalised and selected laboratory-confirmed cases would have underestimated the magnitude of the epidemic. Excess mortality, daily and monthly number of deaths in Belgium were historically high classifying undeniably the first wave of the COVID-19 epidemic as a fatal event.
- 13 November 2020
- Published by Springer Nature in Archives of Public Health
- Vol. 78 (1) , 1-8
Open AccessAll-cause mortality supports the COVID-19 mortality in Belgium and comparison with major fatal events of the last century
Background: The COVID-19 mortality rate in Belgium has been ranked among the highest in the world. To assess the appropriateness of the country’s COVID-19 mortality surveillance, that includes long-term care facilities deaths and deaths in possible cases, the number of COVID-19 deaths was compared with the number of deaths from all-cause mortality. Mortality during the COVID-19 pandemic was also compared with historical mortality rates from the last century including those of the Spanish influenza pandemic. Methods: Excess mortality predictions and COVID-19 mortality data were analysed for the period March 10th to June 21st 2020. The number of COVID-19 deaths and the COVID-19 mortality rate per million were calculated for hospitals, nursing homes and other places of death, according to diagnostic status (confirmed/possible infection). To evaluate historical mortality, monthly mortality rates were calculated from January 1900 to June 2020. Results: Nine thousand five hundred ninety-one COVID-19 deaths and 39,076 deaths from all-causes were recorded, with a correlation of 94% (Spearman’s rho, p < 0,01). During the period with statistically significant excess mortality (March 20th to April 28th; total excess mortality 64.7%), 7917 excess deaths were observed among the 20,159 deaths from all-causes. In the same period, 7576 COVID-19 deaths were notified, indicating that 96% of the excess mortality were likely attributable to COVID-19. The inclusion of deaths in nursing homes doubled the COVID-19 mortality rate, while adding deaths in possible cases increased it by 27%. Deaths in laboratory-confirmed cases accounted for 69% of total COVID-19-related deaths and 43% of in-hospital deaths. Although the number of deaths was historically high, the monthly mortality rate was lower in April 2020 compared to the major fatal events of the last century. Conclusions: Trends in all-cause mortality during the first wave of the epidemic was a key indicator to validate the Belgium’s high COVID-19 mortality figures. A COVID-19 mortality surveillance limited to deaths from hospitalised and selected laboratory-confirmed cases would have underestimated the magnitude of the epidemic. Excess mortality, daily and monthly number of deaths in Belgium were historically high classifying undeniably the first wave of the COVID-19 epidemic as a fatal event.
- Open Access
Belgian COVID-19 Mortality, Excess Deaths, Number of Deaths per Million, and Infection Fatality Rates (8 March - 9 May 2020)
Objective: Scrutiny of COVID-19 mortality in Belgium over the period 8 March – 9 May 2020 (Weeks 11-19), using number of deaths per million, infection fatality rates, and the relation between COVID-19 mortality and excess death rates. Data: Publicly available COVID-19 mortality (2020); overall mortality (2009 – 2020) data in Belgium and demographic data on the Belgian population; data on the nursing home population; results of repeated sero-prevalence surveys in March-April 2020. Statistical methods: Reweighing, missing-data handling, rate estimation, visualization. Results: Belgium has virtually no discrepancy between COVID-19 reported mortality (confirmed and possible cases) and excess mortality. There is a sharp excess death peak over the study period; the total number of excess deaths makes April 2020 the deadliest month of April since WWII, with excess deaths far larger than in early 2017 or 2018, even though influenza-induced January 1951 and February 1960 number of excess deaths were similar in magnitude. Using various sero-prevalence estimates, infection fatality rates (IFRs; fraction of deaths among infected cases) are estimated at 0.38 - 0.73% for males and 0.20 – 0.39% for females in the non-nursing home population (non-NHP), and at 0.79 – 1.52% for males and 0.88 – 1.31% for females in the entire population. Estimates for the NHP range from 38 to 73% for males and over 22 to 37% for females. The IFRs rise from nearly 0% under 45 years, to 4.3% and 13.2% for males in the non-NHP and the general population, respectively, and to 1.5% and 11.1% for females in the non-NHP and general population, respectively. The IFR and number of deaths per million is strongly influenced by extensive reporting and the fact that 66.0% of the deaths concerned NH residents. At 764 (our re-estimation of the figure 735, presented by “Our World in Data”), the number of COVID-19 deaths per million led the international ranking on May 9, 2020, but drops to 262 in the non-NHP. The NHP is very specific: age-related increased risk; highly prevalent comorbidities that, while non-fatal in themselves, exacerbate COVID-19; larger collective households that share inadvertent vectors such as caregivers and favor clustered outbreaks; initial lack of protective equipment, etc. High-quality health care countries have a relatively older but also more frail population [1], which is likely to contribute to this result. Thumbnail summary: What this paper adds: COVID-19 mortality and its relation to excess deaths, case fatality rates (CFRs), infection fatality rates (IFRs), and number of deaths per million are constantly being reported for a large number of countries globally . This study adds detailed insight in the Belgian situation over the period 8 March – 9 May 2020 (Week 11–Week 19) . Belgium has virtually no discrepancy between COVID-19 reported mortality (confirmed and possible cases) and excess mortality. This, combined with a high fraction of possible cases that is COVID-19 related [2] provides a basis for using all COVID-19 cases and thus not only the confirmed ones, in IFR estimation . Against each of the years from 2009 and 2019 and the average thereof, there is a strong excess death peak in 2020, which nearly entirely coincides with confirmed plus possible COVID-19 cases. The excess death/COVID-19 peak rises well above seasonal fluctuations seen in the first trimester during the most recent decade (induced in part by seasonal influenza). In the second week of April 2020, twice as many people died than in the corresponding week of the reference year. April 2020 was the deadliest month of April since WWII, although January 1951 and February 1960 saw similar figures. More recently, in the winter of 2017-2018, there was 4 . 6% excess mortality in Belgium (70,215 actual deaths; 3093 more than the Be-MOMO-model prediction). In the winter of 2016-2017, there was an excess of 3284 deaths (4 . 9% excess mortality) https://epistat.wiv-isp.be/docs/momo/Be-MOMO%20winter%202017-18%20report_FR.pdf . At 764 (our estimate), the number of COVID-19 deaths per million leads the international ranking, but drops sharply to 262 in the non-nursing home population . CFR is not a good basis for international comparison, except as a tool in estimating global infection fatality rates [2]. These authors used asymptotic models to derive IFR as a limit of CFR. CFR is strongly influenced by testing strategy, and in several studies the delay between case confirmation and deaths is not accounted for. The handling of possible cases is ambiguous at best. We do not consider it here . Bias and precision in estimation of IFR is influenced by difficulties surrounding the estimation of sero-prevalence, such as sensitivity and specificity of the tests used [3], time to IgM and in particular IgG seroconversion [4], and potential selection bias occurring in data from residual sample surveys. A sensitivity analysis is undertaken by augmenting one primary with three auxiliary estimates of sero-prevalence . Because in Belgium there is a very close agreement between excess mortality on the one hand and confirmed and possible COVID-19 cases combined on the other, and because an international study [2] suggested that a fraction as high as 0 . 9 of possible cases could be attributable to COVID-19 [5], it is a reasonable choice to use all COVID-19 cases in IFR estimation. This encompasses a large fraction of deaths occurring in nursing homes. The IFR values obtained align with international values [2]. Using various sero-prevalence estimates, IFRs across all ages are estimated at 0 . 38 - 0 . 73% for males and 0 . 20 – 0 . 39% for females in the non-nursing home population (non-NHP), and at 0 . 79 – 1 . 52% for males and 0 . 88 – 1 . 31% for females in the entire population. Estimates for the NHP range from 38 to 73% for males and over 22 to 37% for females. The IFRs rise from nearly 0% under 45 years, to 4 . 3% and 13 . 2% for males in the non-NHP and the general population, respectively, and to 1 . 5% and 11 . 1% for females in the non-NHP and general population, respectively . The IFR is strongly influenced by extensive death cases reporting and the fact that 66 . 0% of the deaths concerned NH residents. Apart from a strong age-related gradient, also for each age category, IFRs are substantially higher in males than in females Because of these dependencies, IFRs should be considered in an age, gender, and sub-population specific manner. The same proviso is made for the number of deaths per million . An important such population is the NHP because of a specific cocktail: age-related increased risk; highly prevalent comorbidities that, while non-fatal in themselves, exacerbate COVID-19; larger collective households that share inadvertent vectors such as caregivers; initial lack of protective equipment, etc. High-quality health care countries have a relatively older but also more frail population [1], which might contribute .
Open AccessBelgian COVID-19 Mortality, Excess Deaths, Number of Deaths per Million, and Infection Fatality Rates (8 March - 9 May 2020)
Objective: Scrutiny of COVID-19 mortality in Belgium over the period 8 March – 9 May 2020 (Weeks 11-19), using number of deaths per million, infection fatality rates, and the relation between COVID-19 mortality and excess death rates. Data: Publicly available COVID-19 mortality (2020); overall mortality (2009 – 2020) data in Belgium and demographic data on the Belgian population; data on the nursing home population; results of repeated sero-prevalence surveys in March-April 2020. Statistical methods: Reweighing, missing-data handling, rate estimation, visualization. Results: Belgium has virtually no discrepancy between COVID-19 reported mortality (confirmed and possible cases) and excess mortality. There is a sharp excess death peak over the study period; the total number of excess deaths makes April 2020 the deadliest month of April since WWII, with excess deaths far larger than in early 2017 or 2018, even though influenza-induced January 1951 and February 1960 number of excess deaths were similar in magnitude. Using various sero-prevalence estimates, infection fatality rates (IFRs; fraction of deaths among infected cases) are estimated at 0.38 - 0.73% for males and 0.20 – 0.39% for females in the non-nursing home population (non-NHP), and at 0.79 – 1.52% for males and 0.88 – 1.31% for females in the entire population. Estimates for the NHP range from 38 to 73% for males and over 22 to 37% for females. The IFRs rise from nearly 0% under 45 years, to 4.3% and 13.2% for males in the non-NHP and the general population, respectively, and to 1.5% and 11.1% for females in the non-NHP and general population, respectively. The IFR and number of deaths per million is strongly influenced by extensive reporting and the fact that 66.0% of the deaths concerned NH residents. At 764 (our re-estimation of the figure 735, presented by “Our World in Data”), the number of COVID-19 deaths per million led the international ranking on May 9, 2020, but drops to 262 in the non-NHP. The NHP is very specific: age-related increased risk; highly prevalent comorbidities that, while non-fatal in themselves, exacerbate COVID-19; larger collective households that share inadvertent vectors such as caregivers and favor clustered outbreaks; initial lack of protective equipment, etc. High-quality health care countries have a relatively older but also more frail population [1], which is likely to contribute to this result. Thumbnail summary: What this paper adds: COVID-19 mortality and its relation to excess deaths, case fatality rates (CFRs), infection fatality rates (IFRs), and number of deaths per million are constantly being reported for a large number of countries globally . This study adds detailed insight in the Belgian situation over the period 8 March – 9 May 2020 (Week 11–Week 19) . Belgium has virtually no discrepancy between COVID-19 reported mortality (confirmed and possible cases) and excess mortality. This, combined with a high fraction of possible cases that is COVID-19 related [2] provides a basis for using all COVID-19 cases and thus not only the confirmed ones, in IFR estimation . Against each of the years from 2009 and 2019 and the average thereof, there is a strong excess death peak in 2020, which nearly entirely coincides with confirmed plus possible COVID-19 cases. The excess death/COVID-19 peak rises well above seasonal fluctuations seen in the first trimester during the most recent decade (induced in part by seasonal influenza). In the second week of April 2020, twice as many people died than in the corresponding week of the reference year. April 2020 was the deadliest month of April since WWII, although January 1951 and February 1960 saw similar figures. More recently, in the winter of 2017-2018, there was 4 . 6% excess mortality in Belgium (70,215 actual deaths; 3093 more than the Be-MOMO-model prediction). In the winter of 2016-2017, there was an excess of 3284 deaths (4 . 9% excess mortality) https://epistat.wiv-isp.be/docs/momo/Be-MOMO%20winter%202017-18%20report_FR.pdf . At 764 (our estimate), the number of COVID-19 deaths per million leads the international ranking, but drops sharply to 262 in the non-nursing home population . CFR is not a good basis for international comparison, except as a tool in estimating global infection fatality rates [2]. These authors used asymptotic models to derive IFR as a limit of CFR. CFR is strongly influenced by testing strategy, and in several studies the delay between case confirmation and deaths is not accounted for. The handling of possible cases is ambiguous at best. We do not consider it here . Bias and precision in estimation of IFR is influenced by difficulties surrounding the estimation of sero-prevalence, such as sensitivity and specificity of the tests used [3], time to IgM and in particular IgG seroconversion [4], and potential selection bias occurring in data from residual sample surveys. A sensitivity analysis is undertaken by augmenting one primary with three auxiliary estimates of sero-prevalence . Because in Belgium there is a very close agreement between excess mortality on the one hand and confirmed and possible COVID-19 cases combined on the other, and because an international study [2] suggested that a fraction as high as 0 . 9 of possible cases could be attributable to COVID-19 [5], it is a reasonable choice to use all COVID-19 cases in IFR estimation. This encompasses a large fraction of deaths occurring in nursing homes. The IFR values obtained align with international values [2]. Using various sero-prevalence estimates, IFRs across all ages are estimated at 0 . 38 - 0 . 73% for males and 0 . 20 – 0 . 39% for females in the non-nursing home population (non-NHP), and at 0 . 79 – 1 . 52% for males and 0 . 88 – 1 . 31% for females in the entire population. Estimates for the NHP range from 38 to 73% for males and over 22 to 37% for females. The IFRs rise from nearly 0% under 45 years, to 4 . 3% and 13 . 2% for males in the non-NHP and the general population, respectively, and to 1 . 5% and 11 . 1% for females in the non-NHP and general population, respectively . The IFR is strongly influenced by extensive death cases reporting and the fact that 66 . 0% of the deaths concerned NH residents. Apart from a strong age-related gradient, also for each age category, IFRs are substantially higher in males than in females Because of these dependencies, IFRs should be considered in an age, gender, and sub-population specific manner. The same proviso is made for the number of deaths per million . An important such population is the NHP because of a specific cocktail: age-related increased risk; highly prevalent comorbidities that, while non-fatal in themselves, exacerbate COVID-19; larger collective households that share inadvertent vectors such as caregivers; initial lack of protective equipment, etc. High-quality health care countries have a relatively older but also more frail population [1], which might contribute .
- 1 March 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 255, 231-236
Short-term effects of nitrogen dioxide on hospital admissions for cardiovascular disease in Wallonia, Belgium
- 1 March 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 255, 231-236
Short-term effects of nitrogen dioxide on hospital admissions for cardiovascular disease in Wallonia, Belgium